 |
Discover ~ Translate ~ Cure |
|
Discover ~ Translate ~ Cure |
| Below is a list of representative publications by individual investigators at the UW Tumor Vaccine Group. To view the article, click on the article title.
You must have Adobe Reader to view these articles. If you do not have Adobe Reader, you can download it free from Adobe.com. |
Original Articles |
|
Concurrent Trastuzumab and HER2/neu-Specific Vaccination in Patients With Metastatic Breast Cancer. Disis ML, Wallace DR, Gooley TA, Dang Y, Slota M, Lu H, Coveler AL, Childs JS, Higgins DM, Fintak PA, Dela Rosa C, Tietje K, Link J, Waisman J, Salazar LG. J Clinical Oncology 27(28):4685-92. (Epub ahead of print 2009) | PubMed# 19720923 |
|
Identification of a broad coverage HLA-DR degenerate epitope pool derived from carcinoembryonic antigen Karyampudi L, Krco CJ, Kalli KR, Erskine CL, Hartmann LC, Goodman K, Ingle JN, Maurer MJ, Nassar A, Yu C, Disis ML, Wettstein PJ, Fikes JD, Beebe M, Ishioka G, and Knutson KL Cancer Immunol Immunother, 2009 (epub ahead of print) |
|
Identification of immunologic biomarkers associated with clinical response after immune-based therapy for cancer Dang Y and Disis ML Annals of the New York Academy of Sciences 1174:81-7. | PubMed #19769740 |
|
Toward a stem cell gene therapy for breast cancer Li Z, Liu Y, Tuve S, Xun Y, Fan X, Min L, Feng Q, Kiviat N, Kiem HP, Disis ML, Lieber A. Blood 113(22): 5423-33, 2009 | PubMed #19329780 |
|
In situ adenovirus vaccination engages T effector cells against cancer. Tuve S, Liu Y, Tragoolpua K, Jacobs JD, Yumul RC, Li ZY, Strauss R, Hellstrom KE, Disis ML, Roffler S, Lieber A. Vaccine 27: 4225-4239, 2009 | PubMed #19481312 |
|
Common adjuvant breast cancer therapies do not inhibit cancer vaccine induced immunity Coveler AL, Goodell V, Webster DJ, Salazar LG, Fintak PA, Childs JS, Higgins DM and Disis ML Breast Cancer Research Treatment 113(1): 95-100, 2009 | PubMed #18236151 |
|
Direct detection of carcinoembryonic antigen autoantibodies in clinical human serum samples using a surface plasmon resonance sensor Ladd J, Lu H, Taylor AD, Goodell V, Disis ML, Jiang S Colloids Surf B Biontefraces 70: 1-6, 2009 | PubMed #19157807 |
|
Insulin-like growth factor-binding protein-2 is a target for the immunomodulation of breast cancer Park KH, Gad E, Goodell V, Dang Y, Wild T, Higgins D, Fintak P, Childs J, Dela Rosa C, Disis ML Cancer Research 68(20): 8400-9, 2008 | PubMed #18922913 |
|
An HLA-DR-degenerate epitope pool detects insulin-like growth factor binding protein 2-specific immunity in patients with cancer Kalli KR, Krco CJ, Hartmann LC, Goodman K, Maurer MJ, Yu C, Johnson EM, Erskine CL, Disis ML, Wettstein PJ, Fikes JD, Beebe M, Ishioka G, Knutson KL Cancer Research 68(12): 4893-901, 2008 | PubMed #18559537 |
|
The endogenous danger signal, crystalline uric acid, signals for enhanced antibody immunity Behrens MD, Wagner WM, Krco CJ, Erskine CL, Kalli KR, Krempski J, Gad EA, Disis ML and Knutson KL Blood 111(3): 1472-9, 2008 | PubMed #18029553 |
|
His-tag ELISA for the detection of humoral tumor-specific immunity Goodell V, McNeel D and Disis ML BMC Immunology 9: 23, 2008 | PubMed #18510754 |
|
Precision and linearity targets for validation of an IFNgamma ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptides Maecker HT, Hassler J, Payne JK, Summers A, Comatas K, Ghanayem M, Morse MA, Clay TM, Lyerly HK, Bhatia S, Ghanekar SA, Maino VC, delaRosa C and Disis ML BMC Immunology 9: 9, 2008 | PubMed #18366814 |
|
An analytical workflow for investigating cytokine profiles Siebert JC, Inokuma M, Waid DM, Pennock ND, Vaitaitis GM, Disis ML, Dunne JF, Wagner DH and Maecker HT Cytometry A 73(4): 289-98, 2008 | PubMed #18163472 |
|
Level of HER-2/neu protein expression in breast cancer may affect the development of endogenous HER-2/neu-specific immunity Goodell V, Waisman J, Salazar LG, dela Rosa C, Link J, Coveler AL, Webster W, Childs JS, Fintak PA, Higgins DM and Disis ML Molecular Cancer Theraputics 7(3): 449-54, 2008 | PubMed #18319334 |
|
Humoral immunity directed against tumor associated antigens as potential biomarkers for the early diagnosis of cancer Lu H, Goodell V, and Disis ML Proteome Res 7: 1388-94, 2008 | PubMed #18311901 |
|
Adoptive transfer of tumor-primed in vitro activated CD4+ T-effectors combined with CD8+ T effectors provides intratumoral T cell proliferation and synergistic anti-tumor response Wang LX, Shu S, Disis ML and Plautz GE Blood 109(11): 4865-76, 2007 | PubMed #17284532 |
|
Sensitivity and specificity of tritiated thymidine incorporation and ELISPOT assays in identifying antigen specific T cell immune responses Goodell V, dela Rosa C, Slota M, MacLeod B and Disis ML BMC Immunology 8: 21, 2007 | PubMed #17850666 |
|
Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo priming Dang Y, Knutson KL, Goodell V, dela Rosa C, Salazar LG, Higgins D, Childs J, Disis ML Clin Cancer Research 13(6):1883-91, 2007 | PubMed #17363545 |
|
Kinetics of tumor-specific T-cell response development after active immunization in patients with HER-2/neu overexpressing cancers Salazar LG, Coveler AL, Swensen RE, Gooley TA, Goodell V, Schiffman K and Disis ML Clinical Immunology 125(3): 275-80, 2007 | PubMed #17913588 |
|
Phenotype and in vitro function of mature MDDC generated from cryopreserved PBMC of cancer patients are equivalent to those from healthy donors Ghanekar SA, Bhatia S, Ruitenberg JJ, delaRosa C, Disis ML, Maino VC, Maeker HT and Waters CA J of Immune Based Terapies & Vaccines 5: 7, 2007 | PubMed #17477875 |
|
Functional T cell responses to tumor antigens in breast cancer patients have a distinct phenotype and cytokine signature Inokuma M, delaRosa C, Schmitt C, Haaland P, Siebert J, Petry D, Tang MX, Suni MA, Ghanekar SA, Gladding D, Dunne JF, Maino VC, Disis ML and Maecker HT J of Immunology 179(4): 2627-33, 2007 | PubMed #17675526 |
|
Emergence of immune escape variant of mammary tumors that has distinct proteomic profile and a reduced ability to induce "danger signals" Manjili MH, Arnouk H, Knutson KL, Kmieciak M, Disis ML, Subjeck JR and Kazim AL Breast Cancer Res Treat 96(3): 233-41, 2006 | PubMed #16211331 |
|
Emergence of immune escape variant of mammary tumors that has distinct proteomic profile and a reduced ability to induce danger signals Manjili MH, Arnouk H, Knutson KL, Kmieciak M, Disis ML, Subjeck JR and Kazim AL Breast Cancer Res Treat 96(3): 243, 2006 | PubMed #16211331 |
|
The tumor antigen repertoire identified in tumor-bearing Neu transgenic mice predicts human tumor antigens Lu H, Knutson KL, Gad E, Disis ML Cancer Research 66(19):9754-61, 2006 | PubMed #17018635 |
|
Recognition of Breast Cancer Cells by CD8+ Cytotoxic Clones Specific for NY-BR-1 Wang W, Epler J, Salazar LG, and Riddell SR Cancer Research 66(13): 6826-33, 2006 | PubMed #16818660 |
|
Tumor Cells Transduced with the MHC Class II Transactivator and CD80 Activate Tumor-Specific CD4+ T Cells Whether or Not They Are Silenced for Invariant Chain Thompson JA, Dissanayake SK, Ksander BR, Knutson KL, Disis ML, and Ostrand-Rosenberg S Cancer Research 66(2): 1147-54, 2006 | PubMed #16424052 |
|
Altered promoter usage characterizes monoallelic transcription arising with ERBB2 amplification in human breast cancers Benz CC, Fedele V, Xu F, Ylstra B, Ginzinger D, Yu M, Moore D, Kneuper-Hall D, Wolff DJ, Disis ML Eppenberger-Castori S, Eppenberger U, Schitulli F, Tommasi S, Paradiso A, Scott GK and Albertson D Genes, Chromosomes and Cancer (2): 983-94, 2006 | PubMed #16883574 |
|
Antibody immunity to the p53 oncogenic proteins is a prognostic indicator in ovarian cancer Goodell V, Salazar LG, Urban N, Drescher C, Gray H, Swensen R, McIntosh MW, and Disis ML Journal of Clinical Oncology 24(5): 762-8, 2006 | PubMed #16391298 |
|
Maximizing the retention of antigen specific lymphocyte function after cryopreservation Disis ML, delaRosa C, Goodell V, Kuan LY, Chang JCC, Kuus-Reichel K, Clay T, Lyerly HK, Waters CA, Ghanekar SA, Maino VC and Maecker HT J of Immunologic Methods 308(1-2): 13-8, 2006 | PubMed #16337957 |
|
Immunoediting of Cancers May Lead to Epithelial to Mesenchymal Transition Knutson KL, Lu H, Stone B, Reiman JM, Behrens MD, Prosperi CM, Gad EA, Smorlesi A, and Disis ML J Immunology 177(3): 1526-33, 2006 | PubMed #16849459 |
|
IL-2 Immunotoxin Therapy Modulates Tumor-Associated Regulatory T Cells and Leads to Lasting Immune-Mediated Rejection of Breast Cancers in neu-Transgenic Mice
Knutson KL, Dang Y, Lu H, Lukas J, Almand B, Gad E, Azeke E, and Disis ML J Immunology 177(1): 84-91, 2006 | PubMed # 16785502 |
|
Antitumor efficacy of CD137 ligation is maximized by the use of a CD137 single-chain Fv–expressing whole-cell tumor vaccine compared with CD137-specific monoclonal antibody infusion Zhang H, Knutson KL, Hellstrom KE, Disis ML, and Hellstrom I Molecular Cancer Therapeutics 5(1): 149-55, 2006 | PubMed # 16432173 |
|
De novo generation of CD4 T cells against viruses present in the host during immune reconstitution Kalina T*, Lu H*, Zhao Z, Blewett E, Dittmer DP, Randolph-Habecker J, Maloney DG, Andrews RG, Kiem HP, and Storek J (*: co-first author) Blood 105(6): 2410-4, 2005 | PubMed #15479725 |
|
Antimetastatic gene expression profiles mediated by retinoic acid beta 2 in MDA-MB-435 breast cancer cells Wallden B, Edmond M, Swift ME, Disis ML and Swisshelm K BMC Cancer 5: 140, 2005 | PubMed #16255778 |
|
Impact of cryopreservation on tetramer, cytokine flow cytometry, and ELISPOT assays Maecker HT, Moon J, Bhatia S, Ghanekar SA, Maino VC, Payne JK, Kuus-Reichel K, Chang J, Summers A, Clay TM, Morse MA, Lyerly HK, delaRosa C, Ankerst DP and Disis ML BMC Immunology 6: 17, 2005 | PubMed #16026627 |
|
Endogenous anti-HER2 antibodies suppress HER2 phosphorylation and signaling through extracellular signal-regulated kinase Montgomery R., Makary E, Schiffman K, Goodell V, and Disis ML Cancer Research 65(2): 650-6, 2005 | PubMed #15695410 |
|
Interleukin-7 improves reconstitution of antiviral CD4 T cells Lu H, Zhao Z, Kalina T, Gillespy T, 3rd, Liggitt D, Andrews RG, Maloney DG, Kiem HP, and Storek J Clin Immunol 114: 30-41, 2005 | PubMed #15596407 |
|
Expression of HLA-DP0401 molecules for identification of DP0401 restricted antigen specific T cells Yang J, Huston L, Berger D, Danke NA, Liu AW, Disis ML and Kwok WW J Clin Immunology 25(5): 428-36, 2005 | PubMed #16160911 |
|
Human tumor cell lysates as a protein source for the detection of cancer antigen specific humoral immunity Goodell V and Disis ML J of Immunologic Methods 299(1-2): 129-38, 2005 | PubMed #15914197 |
|
Clinical Use of Subcutaneous G-CSF or GM-CSF in Malignancy Disis ML Oncology 19(4) Supl 2: 5-9, 2005 | PubMed #15934493 |
|
Neu antigen-negative variants can be generated after neu-specific antibody therapy in neu transgenic mice Knutson, K.L., Almand, B., Dang, Y., et al Cancer Research 64(3): 1146-51, 2004 | PubMed #14871850 |
|
IL-12 enhances the generation of tumor antigen-specific Th1 CD4 T cells during ex vivo expansion Knutson, K.L. and Disis, M.L Clinical Experimental Immunology 135(2): 322-29, 2004 | PubMed #14738463 |
|
Recovery from and consequences of severe iatrogenic lymphopenia (induced to treat autoimmune diseases) Storek J, Zhao Z, Lin E, Berger T, McSweeney PA, Nash RA, Akatsuka Y, Metcalf MD, Lu H, Kalina T, Reindl M, Storb R, Hansen JA, Sullivan KM, Kraft GH, Furst DE, and Maloney DG Clin Immunol 113: 285-98, 2004 | PubMed #15507394 |
|
Humoral epitope spreading following immunization with a HER-2/neu peptide-based vaccine in cancer patients Disis, M.L., Goodell, V., Schiffman, K., and Knutson, K.L J Clinical Immunology 24(5): 571-8, 2004 | PubMed #15359116 |
|
Effect of dose on immune response in patients vaccinated wth an HER-2/neu intracellular domain protein-based vaccine Disis ML, Schiffman K, Guthrie K, Salazar LG, Knutson KL, Gooddell V, dela Rosa C, Cheever MA J Clinical Oncology 22(10): 1916-25, 2004 | PubMed #15143085 |
|
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival Curiel TJ, Coukos G, Zou L, Xavier A, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L and Zou W Nature Med 9: 942-9, 2004 | PubMed #15322536 |
|
Fatal Bacillus cereus sepsis following resolving neutropenic enterocolitis during the treatment of acute leukemia Ginsburg AS, Salazar LG, True LD and Disis ML American J of Hematology 72(3): 204-8, 2003 | PubMed #12605393 |
|
Antigen-Specific Cancer Vaccines Disis ML, Schiffman K, Salazar LG, and Knutson KL ASCO 03: 29-36, 2003 | Not listed in PubMed |
|
Interleukin-7 improves CD4 T-cell reconstitution after autologous CD34 cell transplantation in monkeys Storek J, Gillespy T, 3rd, Lu H, Joseph A, Dawson MA, Gough M, Morris J, Hackman RC, Horn PA, Sale GE, Andrews RG, Maloney DG, and Kiem HP Blood 101(10): 4209-18, 2003 | PubMed #12543864 |
|
Immunization of cancer patients with HER-2/neu-derived peptides demonstrating high-affinity binding to multiple class II alleles
Salazar, L., Fikes, J., Southwood, S., Ishioka, G., Knutson, K., Gooley, T., Schiffman, K. and Disis, M.L Clinical Cancer Research 9(15): 5559-65, 2003 | PubMed #14654536 |
|
Soluble cytokines can act as effective adjuvants in plasmid DNA vaccines targeting self tumor antigen Disis ML, Shiota FM, McNeel DG, Knutson KL Immunobiology 207: 179-86, 2003 | PubMed #12777059 |
|
Pilot study of an HLA-A2 peptide-based vaccine using Flt3 ligand as a systemic vaccine adjuvant McNeel DG, Knutson KL, Schiffman K, Davis D, Caron D and Disis ML J Clinical Immunology 23(1): 62-72, 2003 | PubMed #12645861 |
|
Identification of tumor specific antibodies in patients with breast cancer vaccinated with gene modified allogeneic tumor cells Dols A, Meijer SL, Hu HM, Goodell V, Disis ML, von Mensdorff-Pouilly S, Verheijen R, Alvord WG, Smith J, Urba WJ and Fox BA J Immunotherapy 26(2): 163-70, 2003 | PubMed #12616108 |
|
Plasmid-based vaccines encoding rat neu and immune stimulatory molecules can elicit rat neu-specific immunity Disis, M.L., Scholler, N., Dahlin, A., Pullman, J., Knutson, K., Hellstrom, K. and Hellstrom, I Molecular Cancer Therapeutics 2: 995-1002, 2003 | PubMed #14578464 |
|
Flt3 ligand as a vaccine adjuvant in association with HER-2/neu peptide-based vaccines in patients with HER-2/neu-overexpressing cancers Disis ML, Rinn K, Knutson KL, Davis D, Caron D, dela Rosa C, Schiffman K Blood 99(8): 2845-50, 2002 | PubMed #11929774 |
|
Delayed type hypersensitivity response to recall antigens does not accurately reflect immune competence in advanced stage breast cancer patients Schiffman K, Rinn K, Disis ML Breast Cancer Research and Treatment 74(1): 17–23, 2002 | PubMed #12150448 |
|
Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity Knutson KL, Schiffman K, Cheever MA, Disis ML Clinical Cancer Research 8(5): 1014-8, 2002 | PubMed #12006513 |
|
GMK Progenics Pharmaceuticals Knutson KL Current Opinion in Investigational Drugs 3(1): 159-64, 2002 | PubMed #12054067 |
|
Technology evaluation: DCVax, Northwest Biotherapeutics Knutson KL Current Opinion in Molecular Therapeutics 4(4): 403-7, 2002 | PubMed #1222879 |
|
Update on Breast Cancer Vaccines Schiffman K and Disis ML Diseases of the Breast 5(2): 1-14, 2002 | Not listed in PubMed |
|
Clonal diversity of T cell population responding to a dominant HLA-A2 epitope of HER-2/neu after active immunization in an ovarian cancer patient Knutson KL and Disis ML Human Immunology 63(7): 547–57, 2002 | PubMed #12072190 |
|
Generation of T cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines Disis ML, Gooley TA, Rinn K, Davis D, Piepkorn M, Cheever MA, Knutson KL, Schiffman K J Clinical Oncology 20(11): 2624-32, 2002 | PubMed #12039923 |
|
Inorganic lead activates the mitogen-activated protein kinase kinase-mitogen-activated protein kinase-p90(RSK) signaling pathway in human astrocytoma cells via a protein kinase C-dependent mechanism Lu H, Guizzetti M, and Costa LG J Pharmacol Exp Ther 300: 818-23, 2002 | PubMed #11861786 |
|
Identification of T helper epitopes from prostatic acid phosphatase McNeel DG, Nguyen LD, Disis ML Cancer Research 61(13): 5161–7, 2001 | PubMed #11431355 |
|
Expansion of HER2/neu-specific T cells ex vivo following immunization with a HER2/neu peptide-based vaccine Knutson KL, Disis ML Clinical Breast Cancer 2(1): 73-9, 2001 | PubMed #11899386 |
|
Technology Evaluation: T-cell activator, Xenova Knutson KL Current Opinion in Molecular Therapeutics 3(6): 585-8, 2001 | PubMed #11804273 |
|
Activation of mitogen-activated protein kinase by muscarinic receptors in astroglial cells: role in DNA synthesis and effect of ethanol Yagle K, Lu H, Guizzetti M, Moller T, and Costa LG Glia 35(2): 111-20, 2001 | PubMed #11460267 |
|
Immunologic approaches to the treatment and prevention of cancer Knutson KL IDrugs 4(5): 498-500,2001 | PubMed #16012882 |
|
Immunization with a HER2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients Knutson KL, Schiffman K, Disis ML J Clinical Investigation 107: 477–84, 2001 | PubMed #11181647 |
|
Issues on Clinical Applications of Cancer Vaccines Disis ML and Schiffman K J Immunotherapy 24(2): 104-5, 2001 | PubMed #11265766 |
|
Inorganic lead stimulates DNA synthesis in human astrocytoma cells: role of protein kinase C-alpha Lu H, Guizzetti M, and Costa LG J Neurochem 78: 590-9, 2001 | PubMed #11483662 |
|
Naturally occurring prostate cancer antigen-specific T cell responses of a Th1 phenotype can be detected in patients with prostate cancer McNeel DG, Nguyen LD, Ellis WJ, Higano CS, Lange PH, Disis ML Prostate 47: 222-9, 2001 | PubMed #11351352 |
|
Intracellular signal transduction pathways as targets for neurotoxicants Costa LG, Guizzetti M, Lu H, Bordi F, Vitalone A, Tita B, Palmery M, Valeri P, and Silvestrini B Toxicology 160: 19-26, 2001 | PubMed #11246120 |
|
Immunity to WT-1 in the animal model and in patients with acute myeloid leukemia Gaiger A, Reese V, Disis ML and Cheever MA Blood 96(4): 1480-9, 2000 | PubMed #10942395 |
|
Pre-existant immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer Disis ML, Knutson KL, Schiffman K, Rinn K, McNeel DG Breast Cancer Research and Treatment 62(3): 245–52, 2000 | PubMed #11072789 |
|
Delayed type hypersensitivity response (DTH) is a predictor of peripheral blood T cell immunity after HER-2/neu peptide immunization Disis ML, Schiffman K, Gooley TA, McNeel DG, Rinn K and Knutson KL Clin Cancer Research 6(4): 1347-50, 2000 | PubMed #10778962 |
|
HER-2/neu peptide based vaccines, with GM-CSF as an adjuvant, in patients with advanced stage HER2/neu expressing cancers Schffman K and Disis ML Clin Lung Cancer 2(1): 74-7, 2000 | PubMed #14731345 |
|
Dendritic cells lose ability to present protein antigen after stimulating antigen-specific T cell responses despite upregulation of MHC Class II expression Bernhard H, Huseby ES, Hand SL, Lohmann M, Batten WY, Disis ML, Gralow JR, Meyer zum Bruschenfelde KH, Ohlen C and Cheever MA Immunobiology 201: 568-82, 2000 | PubMed #10834314 |
|
Antibody immunity to prostate cancer-associated antigens can be detected in the serum of patients with prostate cancer McNeel DG, Nguyen LD, Storer BE, Vessella R, Lange PH, and Disis ML J Urology 164: 1825-9, 2000 | PubMed #11025777 |
|
Immunization with recombinant human granulocyte-macrophage colony-stimulating factor as a vaccine adjuvant elicits both a cellular and humoral response to recombinant human granulocyte-macrophage colony-stimulating factor McNeel DG, Schiffman K, Disis ML Blood 93: 2653-9, 1999 | PubMed #10194445 |
|
Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide based vaccine Disis ML, Grabstein KH, Sleath PR and Cheever MA Clin Cancer Research 5: 1289-97, 1999 | PubMed #10389911 |
|
Antibody immunity to the HER-2/neu oncogenic protein in patients with colorectal cancer Ward RL, Hawkins NJ, Coomber D, Disis ML Human Immunology 60: 510–5, 1999 | PubMed #10408800 |
|
Antigen-specific recall urticaria to a peptide-based vaccine Rinn K, Schiffman K, Otero HO and Disis ML J All Clin Immunol 104(1): 240-2, 1999 | PubMed #10400869 |
|
Immunization of metastitic breast cancer patients with CD80-modified breast cancer cells and GM-CSF Schoof DD, Smith JW 2nd, Disis ML, Brant-Zawadski P, Wood W, Doran T, Johnson E Ubra WJ Adv Exp Med Biol 451: 511-8, 1998 | PubMed #10026920 |
|
Human HER-2/neu protein immunization circumvents tolerance to rat neu: A vaccine strategy for "self" tumor antigens Disis ML, Shiota FM and Cheever MA Immunology 93(2): 192-9, 1998 | PubMed #9616368 |
|
Pancreas Transplantation Restores Epinephrine Response and Symptom Recognition During Hypoglycemia in Patients with Long-standing Type I Diabetes and Autonomic Neuropathy Kendall DM, Rooney DP, Smets YFC, Salazar Bolding L, and Robertson RP Diabetes 46(2): 249-57, 1997 | PubMed #9000702 |
|
Identification of HER-2/neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD8 Lustgarten J, Theobald M, Labadie C, LaFace D, Peterson P, Disis ML, Cheever MA and Sherman LA Human Immunology 52(2): 109-18, 1997 | PubMed #9077559 |
|
High titer HER-2/neu protein specific antibody immunity can be detected in patients with breast cancer Disis ML, Pupa SM, Gralow JR, Dittadi R, Menard S and Cheever MA J Clinical Oncology 15(11): 3363-7, 1997 | PubMed #9363867 |
|
Granulocyte-macrophage colony-stimulating factor: An effective adjuvant for protein and peptide-based vaccines Disis ML, Bernhard H, Shiota FM, Hand SL, Gralow JR, Huseby ES, Gillis S and Cheever MA Blood 88(1): 202-10, 1996 | PubMed #8704175 |
|
Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, an oncogenic Self-protein Disis ML, Gralow JA, Bernhard H, Hand SL, Rubin WD, Cheever MA J Immunology 156(9):3151-8, 1996 | PubMed #8617935 |
|
CD4+ T cell immunity to mutated ras protein in pancreatic and colon cancer patients Qin H, Chen W, Takahashi M, Disis ML, Byrd DR, McCahill L, Bertram KA, Fenton RG, Peace DJ and Cheever MA Cancer Research 55(14): 2984-7, 1995 | PubMed #7606715 |
|
Generation of immunostimulatory dendritic cells from human CD34+ hematopoietic progenitor cells of the bone marrow and peripheral blood Bernhard H, Disis ML, Heimfeld S, Hand S, Gralow JR and Cheever MA Cancer Research 55(5): 1099-104, 1995 | PubMed #7532543 |
|
Antibody to ras Proteins in Patients with Colon Cancer Takahashi M, Chen W, Byrd DR, Disis ML, Huseby E, McCahill L, Nelson H, Peace DJ, Qin HL, Shimada H, Okuno K, Yasutomi M and Cheever MA Cin Cancer Research 1(10): 1071-7, 1995 | PubMed #9815896 |
|
In vitro generation of human cytolytic T cells specific for peptides derived from HER-2/neu proto-oncogene protein Disis ML, Smith JW, Murphy AE, Chen W and Cheever MA Cancer Research 54(4): 1071-6, 1994 | PubMed #7508819 |
|
Existent T cell and antibody immunity to HER-2/neu protein in patients with breast cancer Disis ML, Calenoff E, Murphy AE, Chen W, Groner B, Jescke M, Lydon N, McGlynn E, Livingston RB, Moe R and Cheever MA Cancer Reserach 54(1): 16-20, 1994 | PubMed #7505195 |
|
T-cell immunity to oncogenic proteins including mutated ras and chimeric bcr-abl Cheever MA, Chen W, Disis ML, Takahashi M and Peace DJ Ann NY Acad Sci 690: 101-12, 1993 | PubMed #8103658 |
|
Induction of T cells specific for the mutated segment of oncogenic p21ras protein by immunization in vivo with the oncogenic protein Peace DJ, Smith JW, Disis ML, Chen W and Cheever MA J Immunother Emphasis Tumor Immunol 14: 110-4, 1993 | PubMed #7506572 |
|
Circulating immune complexes in cystic fibrosis and their correlation to clinical parameters Disis ML, McDonald TL, Colombo JL, Kobayashi RH, Angle CR and Murray S Pediatric Research 20(5): 385-90, 1986 | PubMed #3714348 |